Medical composition and medical kit
In order to provide (i) a medical composition that has a strong angiogenic effect, has low invasiveness to a body of a patient, and is easy to administer to a living subject and (ii) a medical kit using a medical composition, the medical composition includes: a carrier in a particle form, the carrier having (a) a support made from a bioabsorbable polymer and (b) a surface layer made from hydroxyapatite and provided on the support; and cells provided on a surface of the carrier.
1. A medical composition for injection, the composition comprising:
a carrier in particle form, the carrier having (i) a support made from a bioabsorbable polymer particle and (ii) a surface layer made from hydroxyapatite nanocrystal particles, which have diameters of 25 nm to 500 nm, and provided on the support, wherein the particle diameter of the carrier is not less than 10 μm and not greater than 200 μm; and
a sufficient number of cells, which are effective to generate new blood vessels in a living subject, said cells being adhered directly onto the surface layer of the carrier by adhesive ability of said cells by mixing said carrier and said cells in such a manner that the number, per carrier, of said cells to be mixed is less than or equal to 1×10 10 ;
wherein the composition does not contain gelatin,
wherein the ratio by weight of said carrier to said cells is from 1/10 to 10/1, and
wherein said cells are myelomonocytic cells.
2. The medical composition according to claim 1 , wherein the carrier has a porous structure.
3. The medical composition according to claim 1 , wherein the bioabsorbable polymer is at least one selected from the group consisting of: polylactic acid, polyglycolic acid, polyethylene glycol, propylene glycol, polyhydroxybutylate, polycarbonate, polyamide, cellulose, chitin, chitosan, starch, polyglutamic acid, polydioxanone, cyanoacrylate polymers, polycaprolactone, synthetic polypeptides, hyaluronic acid, polymalic acid, poly butylene succinate, and copolymers of any combination thereof.
4. The medical composition according to claim 1 , further comprising angiogenesis cytokine provided on the surface of the carrier.
5. The medical composition according to claim 4 , wherein the angiogenesis cytokine is at least one selected from the group consisting of: acidic fibroblast growth factor, basic fibroblast growth factor, vascular endothelial growth factor, hepatocyte growth factor, platelet-derived growth factor, platelet-induced growth factor, tumor necrosis factor, epidermal growth factor, angiopoietin, interleukin, hemangiopoietin, sonic hedgehog, transforming growth factor-beta, granulocyte-colony stimulating factor, macrophage-colony stimulating factor, stem cell factor, erythropoietin, thrombopoietin, and FMS-like tyrosine kinase ligand.
6. A medical kit, comprising:
a medical composition recited in claim 1 ; and
an injector for administering the medical composition to a living subject.
7. The medical composition according to claim 1 , wherein fusion bonding between each hydroxyapatite nanocrystal particles is prevented.
8. A method of producing a medical composition, which does not contain gelatin, the method comprising mixing a carrier in particle form and a sufficient number of cells in such a manner that the number, per carrier, of said cells to be mixed is less than or equal to 1×10 10 , the carrier having (i) a support made from a bioabsorbable polymer particle and (ii) a surface layer made from hydroxyapatite nanocrystal particles, which have diameters of 25 nm to 500 nm, and provided on the support; wherein the particle diameter of the carrier is not less than 10 μm and not greater than 200 μm, and wherein the ratio by weight of said carrier to said cells is from 1/10 to 10/1 and said cells are myelomonocytic cells; such that said sufficient number of cells, which are effective to generate new blood vessels in a living subject, are caused to adhere directly onto the surface layer of said carrier by adhesive ability of the cells.